BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26881880)

  • 1. Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients.
    Deng QK; Lei YG; Lin YL; Ma JG; Li WP
    Med Sci Monit; 2016 Feb; 22():516-21. PubMed ID: 26881880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy.
    Wang L; Xie PG; Lin YL; Ma JG; Li WP
    Med Sci Monit; 2014 Aug; 20():1363-8. PubMed ID: 25086586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy.
    Lin YL; Deng QK; Wang YH; Fu XL; Ma JG; Li WP
    Med Sci Monit; 2015 Dec; 21():3955-690. PubMed ID: 26683656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.
    Lin YL; Li YL; Ma JG
    Med Sci Monit; 2017 Oct; 23():4895-4900. PubMed ID: 29026066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
    Lin YL; Xie PG; Wang L; Ma JG
    Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
    Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer.
    Niu WB; Gui SL; Lin YL; Fu XL; Ma JG; Li WP
    Med Sci Monit; 2014 Dec; 20():2584-9. PubMed ID: 25486497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
    Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
    Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphoma.
    Huang W; Xue X; Shan L; Qiu T; Guo L; Ying J; Lu N
    BMC Cancer; 2017 Dec; 17(1):815. PubMed ID: 29202805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer.
    Hou YC; Deng JY; Zhang RP; Xie XM; Cui JL; Wu WP; Hao XS; Liang H
    Cancer Biomark; 2015; 15(5):567-73. PubMed ID: 26406945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-regulated of PCDH10 predicts poor prognosis in hepatocellular carcinoma patients.
    Bing Y; Tian M; Li G; Jiang B; Ma Z; Li L; Wang L; Wang H; Xiu D
    Medicine (Baltimore); 2018 Aug; 97(35):e12055. PubMed ID: 30170418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
    Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
    Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of pathologic prostate-specific antigen mass ratio in patients with localized prostate cancer with negative surgical resection margins.
    Lee S; Jeong CW; Jeong SJ; Hong SK; Choi W; Byun SS; Lee SE
    Urology; 2013 Oct; 82(4):865-9. PubMed ID: 23830078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.